U.S. approves Novartis drug Ilaris to treat childhood arthritis
ZURICH (Reuters) - Novartis said on Friday the U.S. Food and Drug Administration (FDA) had approved its drug Ilaris to treat a serious form of childhood arthritis.Full story
US sues Novartis in NY again, cites doc kickbacks
The U.S. government sued Novartis Pharmaceuticals Corp. again on Friday, saying it paid kickbacks for a decade to doctors to steer patients toward its drugs, sometimes disguising fishing trips off the Florida coast and trips to Hooters restaurants as speaking engagements for the doctors. Full story
U.S. sues Novartis over kickbacks, second case this week
NEW YORK (Reuters) - The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs. Full story
Sponsored Links
Articles
Related Photos
A Novartis logo is pictured on its headquarters building in Mumbai
A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash
File picture of a logo on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln near Basel
File picture of a logo on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln near Basel February 22, 2013. India's highest court has dismissed, April 1, 2013, Swiss drugmaker Novartis AG's petition seeking patent protection for its cancer drug Glivec, a serious blo
File picture showing a general view of Swiss drugmaker Novartis headquarters in Basel
File picture showing a general view of Swiss drugmaker Novartis headquarters in Basel September 1, 2011. India's highest court has dismissed, April 1, 2013, Swiss drugmaker Novartis AG's petition seeking patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms whi
A logo is pictured on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln
A logo is pictured on a building of Swiss drug maker Novartis before its annual general meeting in Pratteln near Basel February 22, 2013. REUTERS/Arnd Wiegmann
Lehner, member of the Board of Directors of Swiss drug maker Novartis addresses the the annual shareholders general meeting in Basel
Ulrich Lehner, member of the Board of Directors of Swiss drug maker Novartis addresses the the annual shareholders general meeting in Basel February 22, 2013. Novartis scrapped plans on February 19, 2013 to pay its outgoing chairman Daniel Vasella 72 million Swiss francs ($78 million) to stop him wo
